THE EFFECT OF IL28B POLYMORPHISMS ON VIROLOGIC RESPONSE TO TREATMENT WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) ADDED TO ABT-450/RITONAVIR (ABT-450/R), ABT-333, OR ABT-072

被引：5
|
作者：
Gaultier, I. [1 ]
Cohen, D. E. [1 ]
Bhathena, A. [1 ]
Idler, K. [1 ]
Larsen, L. M. [1 ]
Podsadecki, T. [1 ]
Bernstein, B. [1 ]
机构：
[1] Abbott, Abbott Pk, IL USA
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)61329-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1327
引用
收藏
页码：S523 / S523
页数：1
相关论文
共 38 条
  • [1] ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus
    Minaei, Ashley Arezou
    Kowdley, Kris V.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (06) : 929 - 937
  • [2] ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection
    Asselah, Tarik
    JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 885 - 888
  • [3] Pharmacokinetics and Safety of Co-administered ABT-450 plus Ritonavir (ABT-450/r), ABT-267 and ABT-333 as a Single Dose in Subjects with Normal Hepatic Function and in Subjects with Mild, Moderate and Severe Hepatic Impairment
    Khatri, Amit
    Gaultier, Isabelle A.
    Menon, Rajeev
    Marbury, Thomas C.
    Lawitz, Eric
    Podsadecki, Thomas J.
    Mullally, Victoria
    Awni, Walid M.
    Bernstein, Barry
    Dutta, Sandeep
    HEPATOLOGY, 2012, 56 : 555A - 556A
  • [4] LACK OF IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON TREATMENT OUTCOME IN THE AVIATOR STUDY WITH ABT-450/R, ABT-333 AND ABT-267, +/- RIBAVIRIN
    Krishnan, P.
    Tripathi, R.
    Irvin, M.
    Beyer, J.
    Reisch, T.
    Schnell, G.
    Xie, W.
    Zhou, X.
    Larsen, L.
    Kofron, J.
    Cohen, D.
    Podsadecki, T.
    Pilot-Matias, T.
    Collins, C.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S498 - S498
  • [5] Characterization of Resistant Variants in NS3 and NS5B Detected in Subjects Treated with ABT-450/r, Ribavirin, and Either ABT-072 or ABT-333 in the Pilot and Co-Pilot Studies Who Experienced Virologic Breakthrough or Relapse
    Pilot-Matias, Tami
    Tripathi, Rakesh L.
    Koev, Gennadiy
    Irvin, Michelle
    Hopkins, Todd
    Menon, Rajeev
    Cohen, Daniel E.
    Podsadecki, Thomas J.
    Bernstein, Barry
    Collins, Christine
    HEPATOLOGY, 2012, 56 : 569A - 570A
  • [6] Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects with Ribavirin Dose Reductions
    Cohen, Daniel E.
    Xie, Wangang
    Larsen, Lois
    Marincic, Christal
    Knauss-Townsend, Mary
    Khatri, Amit
    Podsadecki, Thomas
    Bernstein, Barry
    HEPATOLOGY, 2013, 58 : 754A - 755A
  • [7] Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study
    Kowdley, Kris
    Lawitz, Eric
    Poordad, Fred
    Cohen, Daniel
    Nelson, David
    Zeuzem, Stefan
    Everson, Gregory
    Kwo, Paul
    Foster, Graham
    Sulkowlski, Mark
    Xie, Wangang
    Larsen, Lois
    Khatri, Amit
    Podsadecki, Thomas
    Bernstein, Barry
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S108 - S108
  • [8] ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS
    Lawitz, E.
    Gaultier, I.
    Poordad, F.
    Cohen, D. E.
    Menon, R.
    Larsen, L. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S482 - S482
  • [9] 4-WEEK VIROLOGIC RESPONSE AND SAFETY OF ABT-450 GIVEN WITH LOW-DOSE RITONAVIR (ABT-450/R) IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAiVE SUBJECTS
    Lawitz, Eric
    Gaultier, Isabelle
    Poordad, Fred
    DeJesus, Edwin
    Kowdley, Kris V.
    Sepulveda, Gladys
    Cohen, Daniel E.
    Menon, Rajeev
    Larsen, Lois M.
    Podsadecki, Thomas J.
    Bernstein, Barry
    HEPATOLOGY, 2010, 52 (04) : 878A - 879A
  • [10] A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS
    Lawitz, E.
    Poordad, F.
    Kowdley, K. V.
    Jensen, D.
    Cohen, D. E.
    Siggelkow, S.
    Wikstrom, K.
    Larsen, L.
    Menon, R. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S7 - S7
1234